Shanghai Pharmaceuticals (SPH;HKG: 2607; SHA: 601607) has launched the “SH-INNO incubator,” a collaborative initiative with premier academic institutions and leading scientific research organizations. The incubator is designed to dismantle conventional silos and foster interdisciplinary collaboration among professionals, scholars, corporations, and financiers across the spectrum of “industry, academia, research, medicine, and capital.” This collaborative ecosystem aims to expedite the commercialization of scientific research and bolster the high-quality growth of the biopharmaceutical sector.
Located in ZhangJiang Science City, the incubator is on track to commence operations in September. Spanning an impressive 120,000 square meters, the facility features a robust innovation space for science and technology, modular laboratories, and state-of-the-art research equipment. It has already drawn the interest of key national research institutes, multinational corporation Bayer, Shanghai State-owned Capital Investment, Shanghai Healthcare Capital, and SYNVIDA, which have committed to establishing a presence within the park.
The incubator will concentrate on pioneering innovations in gene and cell therapy, nucleic acid drugs, and conjugate drugs, targeting cutting-edge technologies. It seeks to address the clinical demand in significant disease areas, including autoimmune diseases, oncology, neurological disorders, and rare diseases. Companies interested in innovation are invited to establish their operations within the park through the SH-INNO Mini program accessible on WeChat.- Flcube.com
